322 results on '"Rog, David"'
Search Results
2. Correlates and trajectories of relapses in relapsing–remitting multiple sclerosis
3. Measuring disability in multiple sclerosis: the WHODAS 2.0
4. Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis
5. Prevalence, treatment and correlates of depression in multiple sclerosis
6. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study
7. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis
8. Multiple Sclerosis vision questionnaire (MSVQ-7): Reliability, validity, precision and discrimination
9. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
10. The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications
11. Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29).
12. Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study
13. Ethnic Disparities in the Incidence and Prevalence of Multiple Sclerosis (P4-6.018)
14. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
15. Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy
16. University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register
17. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry
18. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry
19. Inequalities in access to health and social care among adults with multiple sclerosis: A scoping review of the literature
20. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study
21. Ethnic disparities in the epidemiological and clinical characteristics of Multiple Sclerosis
22. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
23. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
24. Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland.
25. Can Autonomous Sensor Systems Improve the Well-being of People Living at Home with Neurodegenerative Disorders?
26. ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK
27. Final Analysis of Pregnancy Outcomes Following Exposure to Dimethyl Fumarate in a Prospective International Registry (S31.004)
28. Outpatient neurology diagnostic coding:a proposed scheme for standardised implementation
29. Outpatient neurology diagnostic coding: a proposed scheme for standardised implementation
30. Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
31. sj-docx-4-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
32. sj-docx-3-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
33. sj-docx-1-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
34. sj-docx-2-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
35. Measuring coping in multiple sclerosis: The Coping Index-MS
36. 151 Updated analysis of pregnancy outcomes for patients with MS in a dimethyl fumarate exposure registry
37. 150 The 70 UK centre multiple sclerosis service and DMT prescribing audit: practical project solutions
38. 135 The UK MS pregnancy register: baseline data from the first fifty enrolled patients
39. 131 Understanding the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis
40. Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines
41. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
42. Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
43. “I'm walking into the unknown': Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment
44. The impact of smoking cessation on multiple sclerosis disease progression
45. PO141 Audit of the first line oral disease modifying treatments in greater manchester
46. 1127 Pregnancy outcomes in alemtuzumab trials and registry design
47. 106 (NOT) comparing apples with apples; MS hospital episode statistics dashboard highlights variation in trusts’ reporting
48. 040 MS disease modifying therapy (DMT) sequencing – natalizumab to cladribine tablets – experience in 20 patients
49. 011 UK variance in DMT advice and prescribing in MS and pregnancy
50. 112 Updated analysis of pregnancy outcomes in a dimethyl fumarate exposure registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.